Schweikert Andreas, Kremer Marcus, Ringel Florian, Liebig Thomas, Duyster Justus, Stüve Olaf, Hemmer Bernhard, Berthele Achim
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Ann Neurol. 2009 Sep;66(3):403-6. doi: 10.1002/ana.21782.
A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.
一名40岁复发缓解型多发性硬化症（MS）患者在接受21剂那他珠单抗单药治疗后发生了原发性中枢神经系统淋巴瘤（PCNSL）。PCNSL是一种老年疾病，大多数患者在70至80岁被诊断出来。免疫缺陷、医源性免疫抑制和一些自身免疫性疾病是已知的易感因素，在这些患者中，PCNSL在40岁时达到发病高峰。由于MS患者中PCNSL的患病率没有增加，且该患者在其他方面没有免疫功能低下，因此不能排除那他珠单抗治疗与PCNSL之间的关联。
